Free Trial

What is Cormark's Estimate for kneat.com FY2025 Earnings?

kneat.com logo with Medical background

Key Points

  • Cormark has reduced its FY2025 earnings per share estimate for kneat.com from ($0.01) to ($0.02), while the consensus estimate stands at ($0.12) per share.
  • Raymond James Financial has decreased its target price for kneat.com shares from C$7.50 to C$7.00, maintaining an "outperform" rating.
  • As of Monday, kneat.com stock opened at C$5.90, with a market capitalization of C$551.66 million and a PE ratio of -63.73.
  • Need better tools to track kneat.com? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

kneat.com, inc. (TSE:KSI - Free Report) - Equities research analysts at Cormark cut their FY2025 earnings per share (EPS) estimates for kneat.com in a report released on Thursday, August 7th. Cormark analyst G. Fairweather now forecasts that the company will post earnings of ($0.02) per share for the year, down from their prior forecast of ($0.01). The consensus estimate for kneat.com's current full-year earnings is ($0.12) per share.

Separately, Raymond James Financial decreased their target price on kneat.com from C$7.50 to C$7.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th.

View Our Latest Analysis on KSI

kneat.com Stock Performance

Shares of kneat.com stock traded down C$0.07 on Monday, hitting C$5.70. The stock had a trading volume of 21,866 shares, compared to its average volume of 93,570. kneat.com has a twelve month low of C$4.50 and a twelve month high of C$7.25. The business's 50 day moving average is C$5.99 and its two-hundred day moving average is C$6.25. The company has a quick ratio of 1.50, a current ratio of 1.43 and a debt-to-equity ratio of 85.50. The stock has a market cap of C$532.96 million, a price-to-earnings ratio of -61.57, a price-to-earnings-growth ratio of 597.67 and a beta of 1.08.

kneat.com Company Profile

(Get Free Report)

kneat.com Inc is in the business of developing and marketing a software application for modelling regulated data-intensive processes for regulated industries, focusing on the life sciences industry. The company has developed Kneat Gx solution which provides management real-time visibility and control and increases product, quality, and compliance.

Recommended Stories

Earnings History and Estimates for kneat.com (TSE:KSI)

Should You Invest $1,000 in kneat.com Right Now?

Before you consider kneat.com, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.

While kneat.com currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines